![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
November 21, 2025
This clinical trial is exploring whether PARP inhibitors will improve outcomes for patients with early-stage pancreas cancer that has BRCA or PALB2 mutations
October 23, 2025
Now Enrolling: EA8231 Study for Patients With Bladder Cancer That Has Progressed Following Treatment
This phase 3 clinical trial is testing a new treatment approach for patients with treatment-refractory locally-advanced or metastatic urothelial cancer
September 5, 2025
This clinical trial is testing a new treatment approach for patients with gastric carcinomatosis
September 19, 2025
Changes broaden eligibility for this study of how adverse life experiences alter genes, immune cells, and subsequent health outcomes
August 28, 2025
This clinical trial aims to improve outcomes by utilizing novel myeloma targeting therapy to reverse kidney failure
August 28, 2025
This study is now assessing blood-based and imaging biomarkers to identify patients at elevated risk of pancreatic cysts becoming cancerous
July 10, 2025
This clinical trial aims to improve survival for high-risk patients by adding a targeted therapy to standard post-surgery immunotherapy
July 10, 2025
In Sarcoma Cancer Awareness Month, we highlight a clinical trial for patients with this rare cancer, which has had few treatment advances
June 11, 2025
The changes broaden eligibility and clarify treatment planning details in this phase 2 trial testing daratumumab-hyaluronidase to eliminate minimal residual disease after initial chemotherapy
April 24, 2025
The changes broaden eligibility for this cancer care delivery study, which aims to improve medication adherence for patients with breast cancer
April 24, 2025
These two trials are open and enrolling adolescent and young adult survivors and patients with cancer
March 21, 2025
The changes significantly broaden eligibility and clarify key details in this phase 3 trial exploring whether adding radiation therapy to standard immunotherapy will improve survival in patients with stable disease after initial treatment